Cardiology and Therapy, 2022 There is limited evidence on therapies for obstructive hypertrophic cardiomyopathy (HCM), and data regarding treatment patterns and cost are scarce. This study assessed treatment patterns and economic outcomes in patients with symptomatic obstructive HCM.
A. Owens +6 more
semanticscholar +1 more source
Changes in left atrial deformation in hypertrophic cardiomyopathy: Evaluation by vector velocity imaging. [PDF]
, 2012 OBJECTIVES: Hypertrophic cardiomyopathy (HCM) represents a generalized myopathic process affecting both ventricular and atrial myocardium. We assessed the global and regional left atrial (LA) function and its relation to left ventricular (LV) mechanics ...
Badran, HM +6 more
core +2 more sources
Stable Rates of Obstructive Hypertrophic Cardiomyopathy in a Contemporary Era
Frontiers in Cardiovascular Medicine, 2022 Hypertrophic cardiomyopathy is the most common genetic heart disease in the US, with an estimated prevalence of 1 in 500. However, the extent to which obstructive hypertrophic cardiomyopathy is clinically recognized is not well-established.
Michael Butzner +5 more
semanticscholar +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 1256-1270, April 2025.Abstract Background and aims The heart is a metabolic organ rich in mitochondria. The failing heart reprograms to utilize different energy substrates, which increase its oxygen consumption. These adaptive changes contribute to increased oxidative stress.
Qinghong Li +12 more
wiley +1 more source
Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy [PDF]
, 2002 Background-Although studies have suggested that "late-onset" hypertrophic cardiomyopathy (HCM) may be caused by sarcomeric protein gene mutations, the cause of HCM in the majority of patients is unknown.
Elliott, PM +6 more
core +1 more source
Left ventricular anatomy in obstructive hypertrophic cardiomyopathy: beyond basal septal hypertrophy
European Heart Journal-Cardiovascular Imaging, 2022 Aims Obstructive hypertrophic cardiomyopathy (oHCM) is characterized by dynamic obstruction of the left ventricular (LV) outflow tract (LVOT). Although this may be mediated by interplay between the hypertrophied septal wall, systolic anterior motion of ...
Uxio Hermida +14 more
semanticscholar +1 more source
Septal radioablation therapy for patients with hypertrophic obstructive cardiomyopathy: first-in-human study [PDF]
, 2023 Xuping Li +17 more
openalex +1 more source
Considerations for drug trials in hypertrophic cardiomyopathy
ESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant +17 more
wiley +1 more source
Hypertrophic obstructive cardiomyopathy: alcohol septal ablation [PDF]
, 2017 Alcohol septal ablation (ASA) was introduced in 1994 as an alternative to septal myectomy for patients with hypertrophic obstructive cardiomyopathy and symptoms refractory to medical therapy.
Fifer, Michael A., Sigwart, Ulrich
core
Contrast-free detection of myocardial fibrosis in hypertrophic cardiomyopathy patients with diffusion-weighted cardiovascular magnetic resonance. [PDF]
, 2015 BackgroundsPrevious studies have shown that diffusion-weighted cardiovascular magnetic resonance (DW-CMR) is highly sensitive to replacement fibrosis of chronic myocardial infarction. Despite this sensitivity to myocardial infarction, DW-CMR has not been
Bi, Xiaoming +6 more
core +2 more sources